Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 PS2-13-03 | DOI: 10.1530/endoabs.101.PS2-13-03

1Irccs Azienda Ospedaliero-Universitaria di Bologna, Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (Dimec), Alma Mater Studiorum University of Bologna, Bologna, Italy; 2Metropolitan Laboratory, Ausl Bologna, Bologna, Italy; 3Irccs Azienda Ospedaliero-Universitaria di Bologna, Division of Endocrinology and Diabetes Prevention and Care, Bologna, Italy


Introduction: Calcitonin (Ct) is the most sensitive serological marker of medullary thyroid carcinoma (MTC). Its assay however is plagued by numerous interferences with consequent high risk of false diagnoses and unnecessary thyroidectomy. Numerous studies have been conducted to identify potential alternative MTC serum markers, among which the most promising one is procalcitonin (proCt). This work aims to present the possible use of proCt in unmasking cases of false hypercalcitoninemia (hyperCt).

Case reports: 4 adult patients were referred to us for recent and incidentally finding of hyperCt. The first patient was a woman with autoimmune thyroiditis, the second one was a smoker woman with multinodular goiter, the third one was a man with rheumatoid arthritis and the last one was a thyroidectomized woman with pancreatic lesion. Calcitonin assay (Immunolite 2000 automated platform, Siemens, Healthcare Diagnostics), calcium gluconate stimulation test (Ca-test) and proCt assay were performed in all patients. Ct after 1:2 and 1:4 dilution, precipitation on PEG and heterophilic Ab test (HBT) were performed in patients #1 and #2. Ct assay on another automated platform (LIAISON Diasorin) was performed in all patients except for patient #4. In patient #1, #2 and #3, Ct assays during Ca-test were substantially unchanged, basal Ct value was lower using a different automated platform and proCt was always undetectable. In patients #1 and #2 the value of basal and stimulated Ct after serial dilution (1:2 and 1:4) were lower than the values obtained in toto. Similar results were also obtained after precipitation on PEG and HBT. Based on this data, we concluded for false hyperCt caused by laboratory interferences. On the contrary, patient #4 presented increased Ct values after the Ca-test, detectable ProCt value and frankly increased Ct values performed on pancreatic lesion eluate, so we concluded for a pancreatic calcitonin-secreting neuroendocrine tumor (NET) (Table 1)

Table 1
PatientBasal Ct (pg/ml)Ct post Calcium gluconate (pg/ml)Ct post-dilution (1:2/1:4) (pg/ml)ProCt (ng/l)Ct assay on other automated platforms (pg/ml)Final Diagnosis
#117519021/<2<0.1<1False hyperCt in patient with autoimmune thyroiditis
#211819629/<2< 0.1<3False hyperCt
#3189192<0.130False hyperCT due to rheumatoid factor interference
#43764610.6130Pancreatic calcitonin-secreting NET

Conclusion: Undetectable proCt values in patients with hyperCt are suggestive of false hyperCt. ProCt could help clinicians in unmasking cases of spurious hyperCt, without the need to perform dilution, precipitation or HBT.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts